非典型3q26/MECOM重排与inv(3)/t(3;3)在急性髓系白血病中基因型拟表
该研究纳入33例携带非典型3q26重排的急性髓系白血病(AML)患者,发现其MECOM受累并伴EVI1过表达,但MDS1-EVI1水平缺失或偏低;重排常涉及髓系发育活跃基因(如CD164、PROM1、CDK6或MYC)的超增强子,超过50%的病例存在等位基因特异性GATA2表达。作者据此提出非典型3q26/MECOM重排与inv(3)/t(3;3)可归为同一类3q26重排AML。
要点
- 非典型3q26重排AML同样表现为EVI1过表达而MDS1-EVI1缺失或偏低。
- 重排常涉及髓系发育基因超增强子,超半数病例伴GATA2等位基因特异性表达。
- 建议常规检测MECOM重排及EVI1、MDS1-EVI1表达以识别3q26重排AML。
核心结论
- 非典型3q26/MECOM重排与inv(3)/t(3;3)共享EVI1过表达、MDS1-EVI1缺失及潜在GATA2受累的白血病机制,可归为单一3q26重排AML实体。
研究设计与样本
- 研究纳入33例携带非典型3q26重排的AML患者进行分析。
主要发现
- 33例非典型3q26重排AML中MECOM受累并伴EVI1过表达,但MDS1-EVI1水平缺失或偏低。
- 这些3q26易位常涉及髓系发育活跃基因(如CD164、PROM1、CDK6或MYC)的超增强子。
- 超过50%的病例观察到等位基因特异性GATA2表达,表现为拷贝数丢失或原因未明的等位基因失衡。
关键数值与推荐
- inv(3)/t(3;3)(q21q26)AML中,GATA2增强子(3q21)易位至MECOM(3q26)导致EVI1过表达及GATA2单等位表达,全长MDS1-EVI1不表达。
- 非典型3q26重排AML中EVI1过表达而MDS1-EVI1缺失或偏低,超过50%病例存在等位基因特异性GATA2表达。
临床怎么用
- 对3q26重排AML应常规分析MECOM重排及EVI1与MDS1-EVI1表达,以识别非典型病例并按单一实体管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) with inv(3)/t(3;3)(q21q26) is a distinct World Health Organization recognized entity, characterized by its aggressive course and poor prognosis. In this subtype of AML, the translocation of a GATA2 enhancer (3q21) to MECOM (3q26) results in overexpression of the MECOM isoform EVI1 and monoallelic expression of GATA2 from the unaffected allele. The full-length MECOM transcript, MDS1-EVI1, is not expressed as the result of the 3q26 rearrangement. Besides the classical inv(3)/t(3;3), a number of other 3q26/MECOM rearrangements with poor treatment response have been reported in AML. Here, we demonstrate, in a group of 33 AML patients with atypical 3q26 rearrangements, MECOM involvement with EVI1 overexpression but no or low MDS1-EVI1 levels. Moreover, the 3q26 translocations in these AML patients often involve superenhancers of genes active in myeloid development (eg, CD164, PROM1, CDK6, or MYC). In >50% of these cases, allele-specific GATA2 expression was observed, either by copy-number loss or by an unexplained allelic imbalance. Altogether, atypical 3q26 recapitulate the main leukemic mechanism of inv(3)/t(3;3) AML, namely EVI1 overexpression driven by enhancer hijacking, absent MDS1-EVI1 expression and potential GATA2 involvement. Therefore, we conclude that both atypical 3q26/MECOM and inv(3)/t(3;3) can be classified as a single entity of 3q26-rearranged AMLs. Routine analyses determining MECOM rearrangements and EVI1 and MDS1-EVI1 expression are required to recognize 3q-rearranged AML cases.
引用
- Ottema S, Mulet-Lazaro R, Beverloo HB, et al. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. Blood. 2020. PMID: 32219447. doi:10.1182/blood.2019003701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。